...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
Author Tag
...
Publisher Tag
...
Topic Tag
...
#Fabio Franchi
...
#Leadership Medica
#HIV Tests
...
#ELISA
...
#Western Blot
...
Page Properties | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
| ||||||||||||
|
Page Properties | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|
| ||||||||||
|
By Fabio Franchi
Leadership Medica Sept. 1998
...
"The task of researchers is to try to falsify as many theories as possible."
-- Karl Popper
...
Dr. Fabio Franchi MD, Specialista in Igiene, Medicina Preventiva e in Malattie Infettive, Trieste
References:
Expand | ||
---|---|---|
| ||
1) Maddox J. Finding wood among the trees. Nature 1988; 335:11. 2) Metcalf JA, Davej Jr. RT and Lane C. Serologic and Virologic tests. In De Vita VT Jr, Hellman S, Rosenberg SA, Curran J, Essex M and Fauci AS. AIDS: Biology, Diagnosis, Treatment and Prevention, 4th edition. Lippincott-Raven Publishers, 1997; pp. 177-195. 3) Ministero della Sanità. Dipartimento per la valutazione dei medicinali e la farmacovigilanza. Linee guida per la terapia antiretrovirale dell'infezione da HIV. Bollettino d'informazione sui farmaci 1996; 6-7:3-13. 4) Commissione Nazionale per la Lotta all'AIDS. Gli screening per gli anticorpi anti-HIV. The Practitioner (ed. it.) 1987; 3:101-120. 5) Voevodin A. HIV screening in Russia (letter). Lancet 1992; 339:1548. 6) Lundberg GD. Serological Diagnosis of Human Immunodeficiency Virus Infection by Western Blot Testing. JAMA 1988; 260:674-679. 7) Ministero della Sanità. AIDS - la diagnosi, il test , il counselling. 1992. 8) Meyer KB and Pauker SG. Screening for HIV: Can we afford the false positive rate? NEJM 1987; 317: 238-241. 9) Zolla-Pazner S. et al. Reinterpretation of HIV Western Blot Patterns. N Eng J Med 1989; 320:1280-1. 10) Midthum K, Garrison L, et al. Frequency of indeterminate Western Blot tests in healthy adults at low risk for HIV infection. J Infect Dis 1990; 162:1379-82. 11) Mac Kenzie WR et al. Multiple False -positive Serologic tests for HIV, HTLV-1, and Hepatitis C Following Influenza Vaccination. Jama 1991; 268:1015-17. 12) Kozhemiakin LA, Bondarenko IG. Genomic instability and AIDS. Biochimiia 1992; 57:1417-1426. 13) Strandstrom HV, Higgins JR, Mossie K, et al. Studies with canine sera that contain antibodies which recognize human immunodeficiency virus structural proteins. Cancer Res 1990; 50:5628s-5630s. 14) Eleopulos EP, Turner VF and Papadimitriou JM. Is a positive Western Blot Proof of HIV Infection? Bio/Technology 1993; 11:696-707. 15) Vogt Advances in virus research. 1965; 11:293-383. 16) Bourinbaiar AS. HIV and GAG. Nature 1991; 349:111. (100 pg p24 equivalent to 1.000.000 HIV particles). 17) Bialy H. Where is the virus? and where is the press? BIO/Technology 1988; 6:121. 18) Bourinbaiar AS. HIV and GAG. Nature 1991; 349:111. 19) Paul DA, Falk LA, Kessler A et al. Correlation of serum HIV antigen and antibody with clinical status in HIV-infected patients. J Med Virol 1987; 22(4): 357-63. 20) Todak G, Klein E, Lange M et al. A clinical appraisal of the p24 Antigen test, p. 326. In: Vol. I, Abstracts VII International Conference on AIDS, Florence, 1991. 21) Delord B, Ottmann M, Schrive MH et al. HIV-1 expression in 25 infected patients: A comparison of RNA PCR, p24 EIA in Plasma and in situ Hybridization in mononuclear cells, p. 113. In: Vol. I, Abstracts VII International Conference on AIDS, Florence, 1991. 22) Genesca J, Jett BW, Epstein JS & Bloggs. What do Western Blot indeterminate patterns for Human Immunodeficiency Virus mean in EIA-negative blood donors? Lancet 1989; ii:1023-1025. 23) Mortimer P, Codd A, Connolly J, et al. Towards error free HIV diagnosis: notes on laboratory practice. Pub Health Lab Service Microbiol Digest 1992; 9:61-64. 24) Valore Predittivo Positivo = VP/(VP+FP); VP = veri positivi, FP = falsi positivi. 25) Poiesz B, Ruscetti FW, Mier JW, et al. T-cell lines established from human T-lymphocytic neoplasias by direct response to T-cell growth factor. Proc Natl Acad Sci 1980; 77:6815-6819. 26) Schüpbach J, Jendis JB, Bron C et al. 1992. False-positive HIV-1 virus cultures using whole blood. AIDS 6: 1545-1546. 27) Gallo RC, Sarin PS and Wu AM. On the nature of the Nucleic Acids and RNA Dependent DNA Polymerase from RNA Tumor Viruses and Human Cells, p. 13-34. In: Possible Episomes in Eukaryotes. LG Silvestri (Ed.). North-Holland Publishing Company, Amsterdam, 1973. 28) Whitkin SS, Higgins PJ and Bendich A. Inhibition of reverse transcriptase and human sperm DNA polymerase by anti-sperm antibodies. Clin Exp Immunol 1978; 33:244-251. 29) Sarngadharan MG, Robert-Guroff M, Gallo RC. DNA polymerases of normal and neoplastic mammalian cells. Biochim Biophysica Acta 1978; 516:419-487. 30) Weissbach A, Baltimore D, Bollum F, et al. Nomenclature of eukaryotic DNA polymerases. Science 1975; 190:401-402. 31) Robert-Guroff M, Schrecker AW, Brinkman BJ, et al. DNA polymerase gamma of human lymphoblasts. Biochem 1977; 16:2866-2873. 32) Lewis BJ, Abrell JW, Smith RG, et al. Human DNA polymerase III (R-DNA): Distinction from DNA polymerase I and reverse transcriptase. Science 1974; 183:867-869. 33) Weissbach A, Baltimore D, Bollum F, et al. Nomenclature of eukaryotic DNA polymerases. Science 1975; 190:40-402. 34) Gallo RC, Salahuddin SZ, Popovic M, et al. Frequent Detection and Isolation of Cytopathic Retroviruses (HTLV-III) from Patients with AIDS and at Risk for AIDS. Science 1984; 224:500-502. 35) Dourmashkin RR, O'Toole CM, Bucher D, Oxford JS. The presence of budding virus-like particles in human Iymphoid cells used for HIV cultivation. Vllth International Conference on AIDS. Florence: 1991:122. 36) Minassian A, Merges M, Garrity R, et al. Induction of a SMRV-like retrovirus from a human T-cell line after treatment with the mutagen ethyl-methyl-sulfonate. J Acquir Immun Defic Syndr 1993; 6 (No 6):738. 37) Gallo RC, Wong-Staal F, Reitz M et al. 1976. Some Evidence For Infectious Type-C Virus in Humans, p. 385-407. In: Animal Virology. D Baltimore, AS Huang, CF Fox (Eds.). Academic Press Inc., New York. 38) Panem S, Prochownik EV, Reale FR et al. Isolation of Type C Virions from a Normal Human Fibroblast Strain. Science 1975; 189:297-299. 39) Panem S, Prochownik EV, Knish WM and Kirsten WH. Cell Generation and Type-C Virus Expression in the Human Embryonic Cell Strain HEL-12. J Gen Virol 1977; 35:487-495. 40) Panem S. C Type Virus Expression in the Placenta. Curr Top Pathol 1979; 66:175-189. 41) Brennan JK, Lichtman MA, Chamberlain, JK and Leblond P. Isolation of Variant Lymphoma Cells with Reduced Growth Requirements for Extracellular Calcium and Magnesium and Enhanced Oncogenicity. Blood 1976; 47:447-459. 42) Garry RF, Fermin CD, Hart DJ et al. Detection of a Human Intracisternal A-Type Retroviral Particle Antigenically Related to HIV. Science 1990; 250:1127-1129. 43) O'Hara CJ, Groopmen JE and Federman M. The Ultrastructural and Immunohistochemical Demonstration of Viral Particles in Lymph Nodes from Human Immunodeficiency Virus-Related Lymphadenopathy Syndromes. Hum Pathol 1988; 19:545. 44) Shaw GM, Hahn BH, Suresh KA et al. Molecular Characterization of Human T-Cell Leukemia (Lymphotropic) Virus Type III in the Acquired Immune Deficiency Syndrome. Science 1984; 226: 1165-1171. 45) Schleupner CJ. Detection of HIV-1 infection. In Mandell/Douglas/Bennet. Principles and Practice of Infectious Diseases. Churchill-Livingstone, IV Edition, 1995: 1253-67. 46) Lanka S. HIV: reality or artifact? Continuum May 1995; 4-9. 47) Imagawa D, Detels R. HIV-1 seronegativehomosexual man. N Engl J Med1991; 325:1250-1. 48) Sloand EM et al. HIV testing - State of the Art (Review). JAMA 1991; 266:2861-6. 49) Defer C et al. Multicentre quality control of polymerase chain reaction for detection of HIV DNA. AIDS 1992; 6:659-63. 50) Busch MP, Henrard DR, Hewlett IK et al. The Transfusion Safety Study Group. Poor sensitivity, specificity, and reproducibility of detection of HIV-1 DNA in serum by polymerase chain reaction. J Acquir Immune Defic Syndr 1992; 5(9): 872-7. 51) Paul MO, Tetali S, Lesser ML et al. Laboratory diagnosis of infection status in infants perinatally exposed to human immunodeficiency virus type 1. J Infect Dis 1996, Jan; 173(1): 68-76. 52) Bootman JS, KItchin PA. An international collaborative study to assess a set of reference reagents for HIV-1 PCR. J Vir Meth 1992; 5:872. 53) Sheppard HW, Ascher MS, Busch MP et al. A multicenter proficiency trial of gene amplification (PCR) for the detection of HIV-1. J Acquir Immune Defic Syndr. 1991; 4(3): 277-83. 54) Schuurman R, Descamps D, Weverling GJ, et al. Multicenter comparison of three commercial methods for quantification of human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol.1996 Dec; 34(12): 3016-22. 55) Ho DD, Neumann AU, Perelson AS, et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995; 373:123-126. 56) Wei X, Ghosh SK, Taylor M, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995; 373:117-122. 57) Simmonds P, Balfe P, Peutherer JF, et al. Human immunodeficiency virus-infected individuals contain provirus in small numbers of peripheral mononuclear cells and at low copy numbers. J Virol 1990; 64:864-872. 58) Maddox J. (review of Hodgkinson book AIDS, the failure of contemporary science) The Guardian Newspaper 1996 July 5th; page 16. 59) Coste J, Montes B, Reynes J, et al. Comparative evaluation of three assays for the quantitation of human immunodeficiency virus type 1 RNA in plasma. J Med Virol. 1996 Dec; 50(4): 293-302. 60) Vandamme AM, Schmit JC, Van Dooren S, et al. Quantification of HIV-1 RNA in plasma: comparable results with the NASBA HIV-1 RNA QT and the AMPLICOR HIV monitor test. J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Oct 1; 13(2): 127-39. 61) Gobbers E, Fransen K, Oosterlaken I, et al. Reactivity and amplification efficiency of the NASBA HIV-1 RNA amplification system with regard to different HIV-1 subtypes. J Virol Methods. 1997 Jul; 66(2): 293-301. 62) Schwartz DH, Laeyendecker OB, Arango Jaramillo S, et al. Extensive evaluation of a seronegative participant in an HIV-1 vaccine trial as a result of false-positive PCR. Lancet 1997 Jul 26; 350(9073): 256-9. 63) Piatak MJ, Saag MS, Yang LC, et al. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science. 1993; 259:1749-1754. 64) Cao Y, Qin L, Zhang L, Safrit J, Ho DD. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N Engl J Med. 1995; 332:201-208. 65) Perelson AS et al. ( Ho D included). HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time . Science 1996; 271:1582-6). 66) Palca J. Draft of Gallo Report Sees the Light of Day. Science 1991; 253:1347-1348. 67) Cohen J. HHS. Gallo Guilty of Misconduct. Science 1993; 259:168-170. 68) Buianouckas FR. HIV an illusion. Nature 1995; 375:197. 69) Eleni Papadopulos Eleopulos, Valendar F Turner, John M Papadimitriou, David Causer. The isolation of HIV - has it really been achieved? Continuum Sept/Oct 1996; 4(3) S:1-24. 70) Brown P. The strains of the HIV war. New Scientist 1991; (25th May):14-15. 71) Salimen MO, Carr JK, Burke DS, et al. Genotyping of HIV-1. The human retroviruses and AIDS Compendium on Line: Web site: http://hiv-web.lanl.gov. USA: US Government, 1996: 30-34. 72) Zhu T, Wang N, Carr A, et al. Evidence or coinfection of multiple strains of human immuodeficiency virus type 1 B an acute seroconvertor. J Virol 1995; 69:1324-1327. 73) Kozal MJ, Shah N, Shen N, et al. Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays. Nat Med 1996; 2:753-759. 74) Gallo R, Wong-Staal F, Montagnier L, Haseltine WA, Yoshida M. HIV/HTLV gene nomenclature. Nature 1988; 333:504. 75) Lazo PA, Tsichlis PN. Biology and pathogenesis of retroviruses. Semin Oncol 1990; 17:269-294. 76) Cunningham AL, Dwyer DE, Mills J, et al. Structure and function of HIV. Med J Aust 1996; 164:161-173. 77) Barré-Sinoussi F. HIV as the cause of AIDS. Lancet 1996; 348:31-35. 78) Wain-Hobson S. Virological mayhem. Nature 1995; 373:102. 79) Blomberg J, Lawoko A, Pipkorn R, et al. A survey of synthetic HIV-1 peptides with natural and chimeric sequences for differential reactivity with Zimbabwean, Tanzanian and Swedish HIV-1-positive sera. AIDS 1993; 7:759-767. 80) Myers G. Nucleic acids alignments and sequences. The human retroviruses and AIDS Compendium on Line: Web site: http://hiv-web.lanl.gov. USA: US Government, 1995: I-1-I-2. 81) Barré-Sinoussi F. HIV as the cause of AIDS. Lancet 1996; 348:31-35. 82) Salimen MO, Carr JK, Burke DS, et al. Genotyping of HIV-1. The human retroviruses and AIDS Compendium on Line: Web site: http://hiv-web.lanl.gov. USA: US Government, 1996: 30-34. 83) Gallo RC, Shaw GM, Markham PD. The etiology of AIDS. In: De Vita V, Hellman S, Rosenberg SA, ed. AIDS etiology, diagnosis, treatment, and prevention. New York: J. B. Lippincott Company, 1985: 31-51. 84) Barré-Sinoussi F, Chermann JC, Rey F. Isolation of a T-Lymphotrophic Retrovirus from a patient at Risk for Acquired Immune Deficiency Syndrome (AIDS). Science 1983; 220:868-871. 85) Klatzmann D, Barr-Sinoussi F, Nugeyre MT. Selective Tropism of Lymphadenopathy Associated Virus (LAV) for Helper-Inducer T Lymphocytes. Science 1984; 225:59-63. 86) Montagnier L. Lymphadenopathy-Associated Virus: From Molecular Biology to Pathogenicity. Annals of Internal Medicine 1985; 103:689-693. 87) Munn RJ, Preston MA, Yamamoto JK, Gardner MB. Ultrastructural comparison of the retroviruses associated with human and simian acquired immunodeficiency syndromes. Laboratory Investigation 1985; 53:194-199. 88) Orenstein JM, Meltzer MS, Phipps T, Gendelman HE. Cytoplasmic assembly and accumulation of human immunodeficiency virus types 1 and 2 in recombinant human colony-stimulating factor-1-treated human monocytes: an ultrastructural study. Journal of Virology 1988; 62:2578-2586. 89) Lanka Stephan. No viral identification: non cloning as proof of isolation! Continuum Feb/March 1997; 4(5):31-33. 90) Gluschankof P, Mondor I, Gelderblom HR, Sattentau QJ. Cell membrane vesicles are a major contaminant of gradient-enriched human immunodeficiency virus type-1 preparations. Virol. 1997; 230:125-133. 91) Bess JW, Gorelick RJ, Bosche WJ, et al. Microvesicles are a source of contaminating cellular proteins found in purified HIV-1 preparations. Virol 1997; 230:134-144. 92) Eleni Papadopulos-Eleopulos. A critique of the evidence for the isolation of HIV (A summary of the views of Papadopulos et al.) Rethinking aids web site (http://www.virusmyth.com/aids ) epsummary.htm 1997. 93) Gelderblom HR, Ozel M, Hausmann EHS, Winkel T, Pauli G, Koch MA. Fine Structure of Human Immunodeficiency Virus (HIV), Immunolocalization of Structural Proteins and Virus-Cell Relation. Micron Microscopica 1988;19:41-60. 94) Hockley DJ, Wood RD, Jacobs JP. Electron Microscopy of Human Immunodeficiency Virus. J Gen Virol 1988; 69:2455-2469. 95) Popovic M, Sarngadharan MG, Read E, et al. Detection, Isolation, and Continuous Production of Cytopathic Retroviruses (HTLV-III) from Patients with AIDS and Pre-AIDS. Science 1984; 224:497-500. 96) Maddox J. Aids research turned upside down. Nature 1991; 353:2. |